Amiodarone-Induced Thyrotoxicosis Clinical Course and Predictors of Outcome by Conen, David et al.
A
r
s
(
d
p
f
a
r
p
t
k
d
F
D
t
2
Journal of the American College of Cardiology Vol. 49, No. 24, 2007
© 2007 by the American College of Cardiology Foundation ISSN 0735-1097/07/$32.00
PHeart Rhythm Disorders
Amiodarone-Induced Thyrotoxicosis
Clinical Course and Predictors of Outcome
David Conen, MD,* Ludovic Melly,* Christoph Kaufmann, MD,* Stefan Bilz, MD,†
Peter Ammann, MD,* Beat Schaer, MD,* Christian Sticherling, MD,* Beat Muller, MD,†
Stefan Osswald, MD, FACC, FESC*
Basel, Switzerland
Objectives This study sought to determine the clinical course and predictors of long-term outcome in patients with docu-
mented amiodarone-induced thyrotoxicosis (AIT).
Background Amiodarone-induced thyrotoxicosis is a condition that is difficult to manage, in particular because of the long
half-life of amiodarone. Data on optimal treatment for AIT are scarce.
Methods We performed a retrospective review among patients with documented AIT at a tertiary care center. Baseline
characteristics, treatment received, laboratory parameters, and events during follow-up were evaluated. The pre-
defined composite end point consisted of the following AIT-associated complications: death, heart transplanta-
tion, hospitalization for heart failure, myocardial infarction, stroke, hospitalization for arrhythmia management,
or hospitalization for treatment complications.
Results Eighty-four patients were included in the present analysis; 27 patients received prednisone for AIT. There was no
difference in time to normalization of free thyroxine between those receiving and those not receiving prednisone.
Long-term follow-up showed high morbidity and mortality; 47 patients (56%) reached the primary end point. Pa-
tients receiving prednisone had a worse outcome than those not receiving prednisone (p  0.003). Although
patients received prednisone for 84  65 days, curves started to separate only 12 months after the initial
diagnosis.
Conclusions Patients with AIT have a high event rate during follow-up. Prednisone had no effect on time to normalization of
thyroxine levels and was associated with an increased event rate. Importantly, AIT-related problems must be
expected late, at a time when thyroid function is under control. (J Am Coll Cardiol 2007;49:2350–5) © 2007
by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.02.054t
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mmiodarone is the most effective drug in maintaining sinus
hythm in patients with atrial fibrillation (1) and in reducing
hock delivery in recipients of an implantable defibrillator
2). Unlike class I and III antiarrhythmic drugs, amiodarone
oes not carry the risk of increased mortality caused by a
roarrhythmic effect (3,4), including in patients with heart
ailure (5).
Although very effective, the use of amiodarone can be
ssociated with significant side effects. Among these, thy-
oid dysfunction is a common manifestation. The exact
revalence and pathogenesis of amiodarone-induced thyro-
oxicosis (AIT) or hypothyroidism, respectively, are un-
nown. The risk of thyroid dysfunction is lower when lower
oses of amiodarone are used (6).
rom the *Department of Cardiology, and the †Department of Endocrinology,
iabetes, and Clinical Nutrition, University Hospital, Basel, Switzerland. The first
wo authors contributed equally to this work.h
Manuscript received August 23, 2006; revised manuscript received February 8,
007, accepted February 12, 2007.Because of the long half-life of amiodarone, AIT may
ake a prolonged course (7). Type 1 AIT occurs in patients
ith pre-existing or “latent” thyroid disease. Type 2 AIT is
form of destructive thyroiditis that develops in patients
ith normal thyroid function at baseline (8) (Table 1).
owever, mixed forms manifesting features of both type 1
nd type 2 disease commonly are found (9). Although
rospective data are scarce (10), type 1 disease is usually
reated with antithyroid drugs and type 2 disease is usually
reated with additional prednisone therapy and/or iopanoic
cid (11). Some refractory cases even need thyroidectomy (12).
Short-term follow-up showed (13) that AIT is associated
ith a higher mortality than thyrotoxicosis because of
raves’ disease. However, no data about the long-term
utcome in patients with AIT are available. Because in these
atients amiodarone with its very long half-life must be
topped most of the time, significant arrhythmia problems
ay occur during long-term follow-up, even after thyroidormone levels have returned to normal.
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June 19, 2007:2350–5 Amiodarone-Induced ThyrotoxicosisThe goal of this study was to examine the clinical
ong-term outcome in patients with AIT. Furthermore,
ifferent treatment regimens for AIT were compared with
egard to the duration of hyperthyroidism and long-term
utcome.
ethods
atients. A retrospective analysis was performed. Eighty-
our patients with a documented diagnosis of AIT between
996 and 2005 were included. Patient charts in the Depart-
ents of Cardiology and Endocrinology at the University
ospital Basel, Switzerland, were screened for cases with a
revious diagnosis of AIT. We defined AIT as a combina-
ion of suppressed thyroid-stimulating hormone (TSH)
evels (below lower reference value) and elevated levels of
ree thyroxine (fT4) and/or triiodothyronine (T3), and
ewly manifesting while the patient was taking amiodarone.
rocedures. All patients alive at follow-up were contacted
or a detailed interview. Medical history was assessed using
structured questionnaire. Additionally, the treating gen-
ral practitioners, cardiologists, and endocrinologists were
ontacted for further information. Data about the date of
nset of AIT, duration of and reason for amiodarone
herapy, comorbidities, left ventricular function at the time
f AIT diagnosis, and previous thyroid disease were col-
ected. Type and duration of therapy for AIT was assessed.
Predefined events occurring during follow-up were iden-
ified using the same data sources. Laboratory parameters
ere retrieved from patient charts and from the archive of
he laboratory of the University Hospital Basel, Switzerland.
aseline and at least 1 follow-up value for TSH and fT4
ere available for all patients. Baseline and follow-up T3
ere available for 53 patients (63%). The present analysis
as approved by the local ethics committee. All contacted
atients provided informed oral consent.
tatistical analysis. Continuous variables are expressed as
edian (interquartile range [IQR]) unless stated otherwise.
ualitative parameters are given as proportions (percent-
ge). Between-group differences for categorical variables
ere compared using the chi-square test or the Fisher exact
est if at least 1 cell had an expected cell count below 5.
ormality of distribution of continuous variables was as-
essed using skewness (1), kurtosis (1), and visual
nspection of the histograms. No variable used for statistical
Differential Diagnosis of AIT
Table 1 Differential Diagnosis of AIT
Type
Pre-existing thyroid disease Yes
Ultrasound Diffuse or nodular g
Doppler sonography Normal or increase
24-h radioiodine uptake Normal or elevated
Thyroid autoantibodies May be present
Response to steroids NoAIT  amiodarone-induced thyrotoxicosis.ests had a normal distribution.
hus, comparisons were made
sing the Mann-Whitney U test.
Two different outcome cate-
ories were analyzed. First, we
nalyzed the time to normaliza-
ion of TSH, fT4, and T3. We
ompared patients receiving and
ot receiving prednisone for AIT
ith regard to the time to nor-
alization of TSH, fT4, and T3.
econd, a composite primary end point was defined before
he data were analyzed. The AIT-related complications,
amely death, heart transplantation, hospitalization for
ongestive heart failure, stroke, myocardial infarction,
rrhythmia-related hospitalization (atrial fibrillation, sus-
ained ventricular arrhythmia, implantation of pacemaker or
efibrillator), and hospitalization for AIT-related treatment
omplication, were included in the primary end point (time
o first event analysis).
Kaplan-Meier curves were constructed, and the outcome
n patients receiving and not receiving prednisone for AIT
as compared using the log-rank test. Because only 6
atients received iopanoic acid during follow-up, no analy-
es were performed for this subgroup. Patients with normal
eft ventricular function, defined as 50% by echocardiog-
aphy, were compared with those with impaired left ven-
ricular function.
Finally, we entered the variables age, gender, history of
oronary artery disease, left ventricular function (normal vs.
bnormal), therapy with prednisone, and fT4 levels at the
ime of AIT diagnosis into a multivariable Cox regression
odel using a backward elimination approach to define
ndependent predictors of outcome. Initially, all variables
ere included in the model, and the least significant variable
as removed until all remaining variables in the model had
value of p  0.1. A 2-tailed p value of 0.05 was
onsidered to indicate statistical significance. All statistical
nalyses were performed with SPSS version 13.0 (SPSS
nc., Chicago, Illinois).
esults
n total, 84 patients with AIT were identified. Baseline
haracteristics and indication for amiodarone therapy are
Abbreviations
and Acronyms
AIT  amiodarone-induced
thyrotoxicosis
fT4  free thyroxine
IQR  interquartile range
T3  triiodothyronine
TSH  thyroid-stimulating
hormone
Type 2 AIT
No
Heterogeneous pattern
Decreased flow
lly 5%/24 h) Very low (typically 2%/24 h)
Usually absent
Usually yes1 AIT
oiter
d flow
(typica
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Amiodarone-Induced Thyrotoxicosis June 19, 2007:2350–5hown in Table 2. Mean ( SD) age was 60 16 years, and
ost of the patients were male. Before AIT was diagnosed,
atients received amiodarone for a median of 935 days (IQR
79 to 1,146 days). Left ventricular function was normal in
9% of the patients based on echocardiography. For 1
atient, no information about left ventricular function was
ound, and for 7 patients, no quantitative measurements
ere available. Symptoms at the time of diagnosis included
nexplained weight loss in 50%, heavy sweating in 42%,
alpitations in 37%, hyperkinesia in 29%, muscle weakness
n 27%, heat intolerance in 24%, overall weakness in 20%,
iarrhea in 12%, and hair loss in 7%. Baseline thyroid values
re shown in Table 2.
Therapy received for AIT is shown in Table 3. The
ajority of patients received antithyroid therapy (83%),
ostly carbimazole. Five patients received carbimazole first
nd propylthiouracil thereafter, all of them because of severe
ide effects of carbimazole, namely agranulocytosis in 4
atients and hepatic side effects in 1 patient. No combina-
ion therapy was used.
In total, 27 patients (32%) received prednisone at a mean
ose of 30  8 mg/day. Mean duration of prednisone
herapy was 84 65 days. The only significant difference in
aseline characteristics between patients with and without
rednisone therapy was that fT4 levels were higher (60
mol/l [IQR 44 to 85 pmol/l] vs. 37 pmol/l [IQR 29 to 63
mol/l], p  0.004) in patients receiving prednisone ther-
py. There was a trend toward lower TSH levels in patients
aseline Characteristics of 84 Patients Withmiodarone-Induced Thyr toxicosis at the Timef Clinical Presentation
Table 2
Baseline Characteristics of 84 Patients With
Amiodarone-Induced Thyrotoxicosis at the Time
of Clinical Presentation
Age (yrs) 60 16
Men (%) 62 (74)
Indication for amiodarone (%)
Atrial fibrillation 48 (57)
Atrial flutter 5 (6)
Left atrial tachycardia 1 (1)
Ventricular tachycardia 27 (32)
Ventricular extrasystole 3 (4)
Duration of amiodarone therapy (months) 31 (19–38)
Coronary heart disease (%) 25 (30)
Previous myocardial infarction 12 (14)
Previous myocarditis 6 (7)
Congenital heart disease 3 (4)
Left ventricular ejection fraction*
50% (%) 26 (31)
50% (%) 57 (69)
Previous thyroid disease 9†
TSH at diagnosis 0.006 (0.005–0.03)
fT4 at diagnosis 44 (31–76)
T3 at diagnosis‡ 2.7 (1.6–3.3)
ata are mean  SD, n (%), or median (interquartile range). *Measured by echocardiography;
vailable for 83 patients only. †Eight patients with euthyroid goiter, 1 patient with Graves’ disease
reated with radioiodine therapy 7 years before the diagnosis of amiodarone-induced thyrotoxico-
is. ‡T3 levels were available for 53 patients.
fT4  free thyroxine; T3  triiodothyronine; TSH  thyroid-stimulating hormone.ith prednisone therapy (0.005 U/l [IQR 0.005 to 0.02 U/l] Ds. 0.008 U/l [IQR 0.005 to 0.08 U/l], p  0.092). In those
ith available T3 levels, there was no difference between
hese 2 groups (2.6 vs. 3.0 ng/ml; p  0.288). Six patients
ere treated with iopanoic acid.
The time course of changes of thyroid hormone levels is
hown in Table 4. Median duration from diagnosis of AIT
o normalization of TSH was longer than normalization of
T4. The shortest time to normalization was found for T3,
lthough only 53 patients could be included in this analysis.
atients with shorter follow-up periods received prednisone
ore frequently than those with longer follow-up (data not
hown).
There was no difference in time to normalization of
irculating thyroid hormone values between patients receiv-
ng and not receiving prednisone. The results did not
hange after exclusion of 15 patients with possible type 1
IT (8 with a history of thyroid nodules and 7 with Graves’
isease or detectable thyroid receptor antibodies). In pa-
ients with available T3 levels, there was a trend toward a
horter time to normalized T3 level in those treated with
rednisone (Table 4).
Thyroidectomy was performed in 8 patients after 112
ays (IQR 82 to 276 days), 5 patients having total and 3
atients having subtotal thyroidectomy. Before the inter-
ention, all individuals received antithyroid therapy, 2 re-
eived prednisone, and 1 received iopanoic acid. Median
T4 level at the time of AIT diagnosis was 71.3 pmol/l
IQR 27.4 to 83.5 pmol/l) compared with 42.0 pmol/l (IQR
1.4 to 65.7 pmol/l) in those without thyroidectomy (p 
.58). Five of these 8 patients (63%) had an adverse event,
ll occurring before thyroidectomy (2 hospitalizations for
eart failure, 2 hospitalizations for atrial fibrillation, and 1
ospitalization for agranulocytosis and fever).
Long-term follow-up showed high morbidity and mor-
ality in all patients (Table 5). Although patients with
educed left ventricular function had a worse outcome
ompared with those who had normal left ventricular
unction (p 0.04), the event rate in the latter was still very
igh (49%). Kaplan-Meier curves up to 60 months (few
vents occurred thereafter) showed early separation of the
urves, although the log-rank test failed to show statistical
ignificance (Fig. 1A).
herapy Received for Hyperthyroidism (n  84)
Table 3 Therapy Received for Hyperthyroidism (n  84)
Antithyroid therapy (%) 70 (83)
Carbimazole 64
Propiothiouracil 11
Both 5
Prednisone (%) 27 (32)
Mean prednisone dose (mg) 30 8
Iopanoic acid (%) 6 (7)
Mean dose of iopanoic acid (mg) 1,000 100
Thyroidectomy (%) 8 (10)
Median time to thyroidectomy (days) 112 (82–276)ata are mean  SD, n (%), or median (interquartile range).
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June 19, 2007:2350–5 Amiodarone-Induced ThyrotoxicosisIn Figure 1B, the event-free survival is shown for patients
eceiving prednisone compared with those not receiving
rednisone. In patients receiving prednisone for AIT ther-
py, the outcome was significantly worse than in patients
ot receiving prednisone (p  0.003). Although patients
eceived prednisone for 84  65 days, the curves did not
tart to separate before 12 months of follow-up, well after
SH normalization (median 4.6 months). More detailed
nalysis of the events showed that mainly the end point
ospitalization for arrhythmia management was different
etween the 2 groups (11 events [41%] in patients receiving
rednisone therapy and 12 events [21%] in patients without
rednisone). In the prednisone and no-prednisone groups,
espectively, 2 and 4 patients had recurrence of ventricular
achycardia, 2 and 2 patients had ventricular fibrillation
2 needed resuscitation and 2 had appropriate implantable
ardioverter-defibrillator shocks), 4 and 3 had hospital-
zation for atrial fibrillation, 1 and 2 needed implantable
ardioverter-defibrillator implantation because amioda-
one had to be stopped, and 2 and 1 needed pacemaker
mplantation.
Finally, multivariate Cox regression analysis showed that
he use of prednisone remained a predictor of the primary
nd point after adjusting for confounding variables (hazard
atio 1.96; 95% confidence interval 1.03 to 3.72).
iscussion
he present analysis confirms that medical therapy for AIT
s challenging. It may take several months before euthyroid-
Time to Normalization of Thyroid Hormone Value
Table 4 Time to Normalization of Thyroid Ho
All (n  84)
Time to normal TSH (days) 138 (92–234)
Time to normal fT4 (days) 103 (63–177)
Time to normal T3 (days)‡ 68 (34–172)
Data are median (interquartile range). *p  0.94 compared with patie
prednisone. ‡Follow-up T3 values available in 53 patients only. §p 
fT4  free thyroxine; T3  triiodothyronine; TSH  thyroid-stimulat
uration of Follow-Up and Incidence of the Primary Composite Endnd in Patients Stratified Ac ording to Left Ventricular Func ion at
Table 5 Duration of Follow-Up and Incidence of the Primary Coand in Patients Stratified According to Left Ventricular
All Patients (n  84)
Duration of follow-up (months) 50 (17–78)
Primary composite end point (%) 47 (56)
Death (%) 16 (19)
Heart transplantation (%) 3 (4)
Hospitalization for heart failure (%) 13 (16)
Stroke (%) 5 (6)
Acute myocardial infarction (%) 3 (4)
Hospitalization for arrhythmia management (%) 23 (27)
Atrial fibrillation 7 (8)
Ventricular fibrillation/tachycardia 10 (12)
Implantation of defibrillator device 7 (8)
Pacemaker implantation 7 (8)
Hospitalization for treatment complication 3 (4)ata are numbers (percentage) or median (interquartile range). *p value is based on a Mann-Whitney Usm can be restored. Furthermore, this is the first analysis
hat shows considerable long-term morbidity and mortality
n affected patients. More than one-half of the patients
eached the primary end point, and nearly 1 in 5 patients
ied. These numbers are substantial considering the rela-
ively young age, the low number of comorbidities, and the
ormal left ventricular function in the majority of patients.
ecause the retrospective design of this analysis does not
llow us to prove any cause-and-effect relationship, further
tudies are required to analyze whether AIT engenders
dverse long-term effects in affected patients.
cute therapy for AIT. Some data from the literature,
xpert opinions, and personal experience suggest a benefit of
rednisone in a subgroup of patients with type 2 AIT (14).
atients treated with prednisone did not have a faster
ecovery of fT4 or TSH levels than patients without
rednisone therapy. Unfortunately, data on T3 levels are not
vailable in a sufficient number of patients. Excluding
atients with probable type 1 AIT did not change these
esults. Higher baseline levels of fT4 suggest that patients
ith more severe disease were treated with prednisone.
We could not identify enough patients treated with
opanoic acid to make valid conclusions. Thyroidectomy was
erformed relatively late. Higher fT4 levels suggest that
atients with the most severe disease underwent surgery.
onsidering the increased event rate, early thyroidectomy
ay be worthwhile in selected cases because definite cure of
IT can be achieved rapidly and long-term amiodarone
herapy can be continued safely. Surgery is an option
e Values
rednisone (n  27) No Prednisone (n  57)
138 (94–220) 141 (90–252)*
98 (53–177) 108 (64–189)†
31 (17–73) 56 (26–84)§
ted with prednisone. †p  0.46 compared with patients treated with
mpared with patients treated with prednisone.
one.
t in All Patientsime of AIT Diagnosis
ite End Point in All Patients
tion at the Time of AIT Diagnosis
Normal EF (n  57) Impaired EF (n  26) p Value
50 (19–78) 44 (16–78) 0.54*
28 (49) 19 (73) 0.04†
8 (14) 8 (31) 0.07†
1 (2) 2 (8) 0.23‡
8 (14) 5 (19) 0.55‡
2 (4) 3 (12) 0.18‡
2 (4) 1 (4) 1.00‡
11 (19) 12 (46) 0.01†
5 (9) 2 (8)
2 (4) 8 (31)
1 (2) 6 (23)
4 (7) 3 (12)
3 (5) 0 0.53‡s
rmon
P
nts treaPointhe T
mpos
Functest. †p value is based on a chi-square test. ‡p value is based on a Fisher exact test.
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Amiodarone-Induced Thyrotoxicosis June 19, 2007:2350–5specially for patients who are too sick to wait for medical
herapy to work. In our patients, surgery was performed
elatively late (after a median of 112 days). Earlier surgery
ight have been more beneficial, and some of the frequent
dverse events in these patients might have been avoided.
n the other hand, complications associated with surgical
herapy in patients with hyperthyroidism also must be
onsidered (12).
ong-term follow-up. We found that patients with abnor-
al left ventricular function (defined as ejection fraction
50% by echocardiography) had more adverse events dur-
Figure 1 Event-Free Survival
Kaplan-Meier event-free survival for patients with normal versus abnormal left
ventricular function (A) and for patients treated with versus without prednisone
(B). Normal ejection fraction (EF) was defined as EF 50% by echocardiogra-
phy (or described as normal in 7 patients). For patients with long follow-up,
follow-up time is censored at 60 months.ng follow-up. These results confirm the prognostic impor- cance of reduced left ventricular function (15). However, the
resence of left ventricular dysfunction failed to be an
ndependent predictor of the primary end point in the
ultivariate analysis. This may be related to reduced statis-
ical power because of the low number of patients in the
roup with reduced left ventricular function. Alternatively,
fter AIT patients may remain at high long-term risk,
educing the influence of left ventricular function on out-
ome. This especially may be true when amiodarone as the
ost effective antiarrhythmic drug must be discontinued
ermanently.
Therefore, with regard to the high incidence of
rrhythmia-related events during long-term follow-up, con-
inuation of amiodarone despite the occurrence of AIT may
e considered as a therapeutic option. Some uncontrolled
nalyses suggest that amiodarone may be continued safely
uring and after AIT (16,17). However, prospective con-
rolled data about continued amiodarone therapy in patients
ith AIT are needed.
linical implications. In patients with AIT, the high
vent rate suggests the need for close monitoring. The acute
herapy should be carefully selected. Clinical examination,
hyroid ultrasound and Doppler sonography (18), assess-
ent of radioiodine uptake (19), and certain biomarkers
uch as interleukin-6 (20) may be helpful in selecting those
IT patients who may benefit from prednisone therapy.
arly favorable response to a short course of prednisone
ight be another criterion for finding those patients who
enefit from continuation of steroid therapy until restora-
ion of euthyroidism. Patients with severe disease and a poor
esponse to medical therapy are candidates for early
hyroidectomy.
Because the findings from this analysis suggest that
atients with AIT are at risk for complications during a long
eriod of time, prolonged follow-up visits after normaliza-
ion of thyroid function should be recommended. In par-
icular, clinicians should look for overt or silent arrhythmia
ecurrence, the most common complication during long-
erm follow-up.
tudy limitations. First, a retrospective nonrandomized
nalysis was performed. Although we adjusted for con-
ounding factors, residual confounding cannot be excluded.
econd, the study design precludes the establishment of a
ausal relationship. Third, we included a predominantly
aucasian population without iodine deficiency, and the
esults may not be generalizable to other populations.
ourth, although this is one of the largest cohorts of
atients with AIT in the literature, some subgroups exam-
ned were small. Fifth, T3 levels were not available for all
atients. Finally, no systematic approach has been used to
istinguish patients with type 1 and type 2 AIT. Thus, the
rescribing pattern and patient selection for prednisone
herapy may have changed over time. Prednisone may have
een used as a second-line therapy in some patients. Both
ould have contributed to the finding that prednisone was
n
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June 19, 2007:2350–5 Amiodarone-Induced Thyrotoxicosisot associated with a more rapid recovery of thyroid
ormone levels.
onclusions
atients with AIT have high morbidity and mortality
uring long-term follow-up. Importantly, AIT-related ad-
erse events must be expected late during follow-up, at a
ime when thyroid function is under control. Furthermore,
rednisone was not associated with a shorter time to
ormalization of fT4 levels in this retrospective analysis.
urther studies should evaluate which patients may be safely
reated with prednisone during the acute phase, and in
hich patients amiodarone may be continued without the
isk of recurrent AIT.
eprint requests and correspondence: Dr. Stefan Osswald,
ardiology, University Hospital, Petersgraben 4, 4031 Basel,
witzerland. E-mail: sosswald@uhbs.ch.
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